soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study NEJM Editorial Fellow Harleen Marwah,

Table of Contents: How does Ozempic work for weight loss

combines GLP-1 and GIP receptor activity and shows strong weight loss effects

Shauna Levy, M.D., an obesity and medical weight-loss specialist and assistant professor at Tulane University School of Medicine in New Orleans

Sem-O Tablet is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise

GLP-1 medications, including the oral semaglutide pill, are generally well-tolerated by many patients

13.2% of participants developed gastrointestinal events on tirzepatide, but overall, the participants experienced greater weight reduction